Related Experiment Video
Updated: Jun 27, 2025
Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
Antibody-free time-resolved terbium luminescence assays designed for cyclin-dependent kinase 5 (CDK5)
Abstract:
Novel time-resolved terbium luminescence assays were developed for CDK5 and CDK2 by designing synthetic substrates which incorporate phospho-inducible terbium sensitizing motifs with kinase substrate consensus sequences. Substrates designed for CDK5 showed no phosphorylation by CDK2, opening the possibility for CDK5-specific assay development for selective drug discovery.
Insights
Novel terbium luminescence assays were created for CDK5 and CDK2 using synthetic substrates. These assays enable specific drug discovery for CDK5, as CDK2 did not phosphorylate the CDK5-designed substrates.
Area of Science:
- Biochemistry
- Biophysics
- Drug Discovery
Background:
- Cyclin-dependent kinases (CDKs) play crucial roles in cell cycle regulation.
- Dysregulation of CDK activity is implicated in various diseases, including cancer.
- Developing selective assays for specific CDKs is essential for targeted therapeutic development.
Approach:
- Developed novel time-resolved terbium luminescence assays.
- Designed synthetic substrates incorporating phospho-inducible terbium sensitizing motifs.
- Utilized kinase substrate consensus sequences for substrate design.
Key Points:
- The assays are designed for Cyclin-Dependent Kinase 5 (CDK5) and Cyclin-Dependent Kinase 2 (CDK2).
- Substrates specifically designed for CDK5 demonstrated no phosphorylation by CDK2.
- This selectivity is crucial for developing CDK5-specific assays.
Conclusions:
- Established novel terbium luminescence assays for CDK5 and CDK2.
- Demonstrated the potential for CDK5-specific assay development.
- These assays facilitate selective drug discovery targeting CDK5.
